Abstract
Rubidazone, the new semi synthetic benzol hydrazone hydrochloride derivative of daunorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumors and human acute leukaemias. The authors have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemia CFU dose survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7.8 and 7.5, respectively. This near identity of efficacy ratios for rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 64-68 |
| Number of pages | 5 |
| Journal | British Journal of Cancer |
| Volume | 34 |
| Issue number | 1 |
| State | Published - 1976 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Rubidazone vs adriamycin : an evaluation of their differential toxicity in the spleen colony assay system. / Alberts, David S; Van Daalen Wetters, T.
In: British Journal of Cancer, Vol. 34, No. 1, 1976, p. 64-68.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rubidazone vs adriamycin
T2 - an evaluation of their differential toxicity in the spleen colony assay system
AU - Alberts, David S
AU - Van Daalen Wetters, T.
PY - 1976
Y1 - 1976
N2 - Rubidazone, the new semi synthetic benzol hydrazone hydrochloride derivative of daunorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumors and human acute leukaemias. The authors have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemia CFU dose survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7.8 and 7.5, respectively. This near identity of efficacy ratios for rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.
AB - Rubidazone, the new semi synthetic benzol hydrazone hydrochloride derivative of daunorubicin, has proved on a molecular weight basis to be less toxic than adriamycin and similar to daunorubicin in cardiac toxicity studies in the hamster as well as in other in vivo and in vitro test systems. It has proven effectiveness against several animal tumors and human acute leukaemias. The authors have compared the inhibitory effect of rubidazone to that of adriamycin on P388 leukaemia and normal bone marrow colony forming units (CFU) using the spleen colony assay system in male DBA2 mice. The efficacy ratios (i.e., the ratio of the slopes of the normal bone marrow CFU to leukaemia CFU dose survival curves) in the spleen colony assay system for rubidazone and adriamycin were 7.8 and 7.5, respectively. This near identity of efficacy ratios for rubidazone and adriamycin correlated with the results of median survival time studies in the leukaemic mice. Their dose median survival time curves were almost parallel, having nearly identical slopes. Rubidazone's equal therapeutic index as compared to adriamycin in the spleen colony assay system together with its known decreased toxicity to cardiac muscle cells makes it an extremely promising new anthracycline derivative to study in comparison to adriamycin in human malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0017182544&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017182544&partnerID=8YFLogxK
M3 - Article
C2 - 952715
AN - SCOPUS:0017182544
VL - 34
SP - 64
EP - 68
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 1
ER -